• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微型T细胞受体:用于从诱导多能干细胞生成T细胞的截短型T细胞受体。

Mini-TCRs: Truncated T cell receptors to generate T cells from induced pluripotent stem cells.

作者信息

Takayanagi Shin-Ichiro, Wang Bo, Hasegawa Saki, Nishikawa Satoshi, Fukumoto Ken, Nakano Kohei, Chuganji Sayaka, Kato Yuya, Kamibayashi Sanae, Minagawa Atsutaka, Kunisato Atsushi, Nozawa Hajime, Kaneko Shin

机构信息

Kirin Central Research Institute, Kirin Holdings Company, Ltd., 26-1, Muraoka-Higashi 2, Fujisawa-shi, Kanagawa 251-8555, Japan.

Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.

出版信息

Mol Ther Methods Clin Dev. 2023 Sep 16;31:101109. doi: 10.1016/j.omtm.2023.101109. eCollection 2023 Dec 14.

DOI:10.1016/j.omtm.2023.101109
PMID:37822720
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10562677/
Abstract

Allogeneic T cell platforms utilizing induced pluripotent stem cell (iPSC) technology exhibit significant promise for the facilitation of adoptive immunotherapies. While mature T cell receptor (TCR) signaling plays a crucial role in generating T cells from iPSCs, the introduction of exogenous mature TCR genes carries a potential risk of causing graft-versus-host disease (GvHD). In this study, we present the development of truncated TCRα and TCRβ chains, termed mini-TCRs, which lack variable domains responsible for recognizing human leukocyte antigen (HLA)-peptide complexes. We successfully induced cytotoxic T lymphocytes (CTLs) from iPSCs by employing mini-TCRs. Combinations of TCRα and TCRβ fragments were screened from mini-TCR libraries based on the surface localization of CD3 proteins and their ability to transduce T cell signaling. Consequently, mini-TCR-expressing iPSCs underwent physiological T cell development, progressing from the CD4 and CD8 double-positive stage to the CD8 single-positive stage. The resulting iPSC-derived CTLs exhibited comparable cytokine production and cytotoxicity in comparison to that of full-length TCR-expressing T lymphocytes when chimeric antigen receptors (CARs) were expressed. These findings demonstrate the potential of mini-TCR-carrying iPSCs as a versatile platform for CAR T cell therapy, offering a promising avenue for advancing adoptive immunotherapies.

摘要

利用诱导多能干细胞(iPSC)技术的同种异体T细胞平台在促进过继性免疫疗法方面显示出巨大潜力。虽然成熟的T细胞受体(TCR)信号传导在从iPSC产生T细胞的过程中起着关键作用,但引入外源性成熟TCR基因存在引发移植物抗宿主病(GvHD)的潜在风险。在本研究中,我们展示了截短的TCRα和TCRβ链(称为微型TCR)的开发,它们缺乏负责识别人类白细胞抗原(HLA)-肽复合物的可变结构域。我们通过使用微型TCR成功地从iPSC诱导出细胞毒性T淋巴细胞(CTL)。基于CD3蛋白的表面定位及其转导T细胞信号的能力,从微型TCR文库中筛选TCRα和TCRβ片段的组合。因此,表达微型TCR的iPSC经历了生理性T细胞发育,从CD4和CD8双阳性阶段发展到CD8单阳性阶段。当表达嵌合抗原受体(CAR)时,所得的iPSC来源的CTL与表达全长TCR的T淋巴细胞相比,表现出相当的细胞因子产生和细胞毒性。这些发现证明了携带微型TCR的iPSC作为CAR T细胞疗法通用平台的潜力,为推进过继性免疫疗法提供了一条有前景的途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/441cf0eff097/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/ebe1e12a6b15/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/19a2bcddef0a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/7e7963c32c0c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/65b54bf14394/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/f03808b961b3/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/4f90d623e880/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/b71c7468c8b6/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/441cf0eff097/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/ebe1e12a6b15/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/19a2bcddef0a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/7e7963c32c0c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/65b54bf14394/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/f03808b961b3/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/4f90d623e880/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/b71c7468c8b6/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c34/10562677/441cf0eff097/gr7.jpg

相似文献

1
Mini-TCRs: Truncated T cell receptors to generate T cells from induced pluripotent stem cells.微型T细胞受体:用于从诱导多能干细胞生成T细胞的截短型T细胞受体。
Mol Ther Methods Clin Dev. 2023 Sep 16;31:101109. doi: 10.1016/j.omtm.2023.101109. eCollection 2023 Dec 14.
2
Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.诱导多能干细胞衍生嵌合抗原受体 T 细胞:干细胞与免疫疗法的交汇点。
Cell Reprogram. 2023 Oct;25(5):195-211. doi: 10.1089/cell.2023.0041. Epub 2023 Sep 29.
3
Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.慢性 TCR-MHC(自身)相互作用限制了 TCR 亲和力增加的 CD8 T 淋巴细胞的功能潜力。
J Immunother Cancer. 2019 Nov 5;7(1):284. doi: 10.1186/s40425-019-0773-z.
4
Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities.源自造血前体细胞的抗原受体重定向T细胞缺乏内源性TCR/CD3受体的表达,并表现出特定的抗肿瘤能力。
Oncoimmunology. 2017 Jan 19;6(3):e1283460. doi: 10.1080/2162402X.2017.1283460. eCollection 2017.
5
Regeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes.通过外源性TCR基因转导的诱导多能干细胞再生肿瘤抗原特异性细胞毒性T淋巴细胞。
Mol Ther Methods Clin Dev. 2020 Sep 20;19:250-260. doi: 10.1016/j.omtm.2020.09.011. eCollection 2020 Dec 11.
6
Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.携带天然T细胞受体(TCR)的工程化T细胞与基于TCR样抗体的嵌合抗原受体的功能比较表明了亲和力/亲合力阈值。
J Immunol. 2014 Dec 1;193(11):5733-43. doi: 10.4049/jimmunol.1301769. Epub 2014 Oct 31.
7
Generation of induced pluripotent stem cell (iPSC) from NY-ESO-I-specific cytotoxic T cells isolated from the melanoma patient with minor HLAs: The practical pilot study for the adoptive immunotherapy for melanoma using iPSC technology.从患有轻度人类白细胞抗原(HLA)的黑色素瘤患者中分离出的NY-ESO-I特异性细胞毒性T细胞诱导生成诱导多能干细胞(iPSC):使用iPSC技术进行黑色素瘤过继性免疫治疗的实际初步研究。
Exp Dermatol. 2023 Feb;32(2):126-134. doi: 10.1111/exd.14686. Epub 2022 Oct 21.
8
Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells.肿瘤反应性肿瘤浸润淋巴细胞重编程为人类诱导多能干细胞。
Cancer Res Commun. 2023 May 25;3(5):917-932. doi: 10.1158/2767-9764.CRC-22-0265. eCollection 2023 May.
9
Regeneration of antigen-specific T cells by using induced pluripotent stem cell (iPSC) technology.利用诱导多能干细胞(iPSC)技术再生抗原特异性 T 细胞。
Int Immunol. 2021 Nov 25;33(12):827-833. doi: 10.1093/intimm/dxab091.
10
CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products.用 CAR NK-92 细胞清除残留 TCR+细胞,以获得超高纯度的异体 TCR 缺失 CAR T 细胞产品。
Blood Adv. 2023 Aug 8;7(15):4124-4134. doi: 10.1182/bloodadvances.2022009397.

本文引用的文献

1
Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.利用新型高灵敏度 aCD22 CAR 对 B-ALL 进行 CD19 和 CD22 的双重靶向治疗。
Mol Ther. 2023 Jul 5;31(7):2089-2104. doi: 10.1016/j.ymthe.2023.03.020. Epub 2023 Mar 21.
2
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.复发/难治性多发性骨髓瘤中同种异体靶向BCMA的CAR T细胞:1期UNIVERSAL试验中期结果
Nat Med. 2023 Feb;29(2):422-429. doi: 10.1038/s41591-022-02182-7. Epub 2023 Jan 23.
3
Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells.
优化源自人诱导多能干细胞的嵌合抗原受体 T 细胞的增殖和持久性。
Nat Biomed Eng. 2023 Jan;7(1):24-37. doi: 10.1038/s41551-022-00969-0. Epub 2022 Dec 12.
4
Valemetostat Tosilate: First Approval.托沙替尼酯:首次批准。
Drugs. 2022 Nov;82(16):1621-1627. doi: 10.1007/s40265-022-01800-5.
5
Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells.从 T 细胞衍生的诱导多能干细胞生成 TCR 阴性 CD8αβ+ CAR T 细胞。
Nat Biomed Eng. 2022 Nov;6(11):1284-1297. doi: 10.1038/s41551-022-00915-0. Epub 2022 Aug 8.
6
EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity.EZH1 抑制可产生具有增强抗肿瘤活性的成熟 iPSC 来源的 CAR T 细胞。
Cell Stem Cell. 2022 Aug 4;29(8):1181-1196.e6. doi: 10.1016/j.stem.2022.06.014.
7
Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy.通过多能性重编程生成高增殖、年轻化的细胞毒性 T 细胞克隆,用于过继免疫治疗。
Mol Ther. 2021 Oct 6;29(10):3027-3041. doi: 10.1016/j.ymthe.2021.05.016. Epub 2021 May 21.
8
Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells.从基因工程同种异体人诱导多能干细胞中生成低免疫原性 T 细胞。
Nat Biomed Eng. 2021 May;5(5):429-440. doi: 10.1038/s41551-021-00730-z. Epub 2021 May 17.
9
Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer.关于现成的嵌合抗原受体T细胞/自然杀伤细胞用于癌症治疗的当前观点
Cancers (Basel). 2021 Apr 16;13(8):1926. doi: 10.3390/cancers13081926.
10
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany.德国嵌合抗原受体 T(CAR-T)和嵌合抗原受体自然杀伤(CAR-NK)细胞疗法临床试验的现状和展望。
Gene Ther. 2021 Sep;28(9):513-527. doi: 10.1038/s41434-021-00246-w. Epub 2021 Mar 22.